There are currently 2699 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06313437
Recruiting
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Re... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Cystic Fibrosis
Register for Updates
Advanced Imaging for Pulmonary Fibrosis
NCT06532071
Recruiting
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Fibrosis
Register for Updates
Early Intervention in High Risk CCUS
NCT06802146
Recruiting
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clonal Cytopenia of Undetermined Significance, Cytopenia
Register for Updates
ctDNA in Cutaneous Squamous Cell Carcinoma
NCT06875609
Recruiting
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Cutaneous Squamous Cell Carcinoma
Register for Updates
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727
Recruiting
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/22/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Glycogen Storage Disease
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
PV Loop & Coarctation Study
NCT05362721
Recruiting
Coarctation of the aorta accounts for 4-7% of all congenital heart disease. While stent therapy, when feasible, is the standard of care for coarctation, it may not completely improve the work (and afterload) of the heart due to its effects on the elasticity of the aorta. This study will provide the information needed to understand the effects of current management on the cardiac mechanics and work.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/21/2025
Locations: Children's Hospital of Boston, Boston, Massachusetts
Conditions: Coarctation of Aorta
Register for Updates
High-flow Nasal Oxygen Therapy for Advanced Endoscopy in High-risk Patients.
NCT06610461
Recruiting
Anesthesia is crucial during upper GI endoscopy in order to improve the procedural conditions for the interventionist, increase the quality of examination and alleviate patient discomfort. However, sedation during endoscopy carries a serious risk of blood oxygen desaturation. This study aims to investigate the hypothesis if the application of high-flow nasal oxygen (HFNO) during high-risk gastroscopy reduces the risk of blood oxygen levels to drop below a defined threshold. Enrolled patients wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Anesthesia, Critical Care and Pain Medicine Department at Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Hypoxemia During Surgery
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Sauna for Long Covid
NCT05931497
Recruiting
Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/20/2025
Locations: Depression Clinical and Research Program, Boston, Massachusetts
Conditions: Long COVID
Register for Updates
EIM Via the Myolex MScan As an ALS Biomarker
NCT06491732
Recruiting
Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates